TABLE 2.
Plasma pharmacokinetic (PK) parameters obtained after the third SPR206 100 mg intravenous dose (PK population)a
| Parameter | Arithmetic mean (SDb) | Geometric mean (CVc%) |
|---|---|---|
| AUC0-8 (h*ng/mL)d | 20120.7 (3555.2) | 19817.9 (17.9) |
| Cmaxe (ng/mL) | 4395.0 (752.7) | 4333.4 (17.2) |
| Cminf (ng/mL) | 1409.9 (709.4) | 1306.9 (36.7) |
| Tmaxg (hours) | 2.1 (0.2) | 2.1 (7.4) |
| t1/2h (hours) | 3.6 (0.5) | 3.6 (13.5) |
| Vzi (mL) | 19806.1 (3533.7) | 19502.1 (18.1) |
a
PK population included all the subjects who received at least one dose of SPR206 and had at least one evaluable plasma concentration. d, h, and i, N = 32; e, f, and g, N = 34.
b
SD, standard deviation.
c
CV, coefficient of variation.
d
AUC0-8, area under the concentration-time curve from time zero to 8 h.
e
Cmax, maximum plasma concentration.
f
Cmin, minimum plasma concentration.
g
Tmax, time to Cmax.
h
t1/2, half-life.
i
Vz, volume of distribution at the terminal phase.